Top Page
Day One Biopharmaceuticals
(NASDAQ:DAWN)
Day One Biopharmaceuticals (DAWN) vs. SPDR S&P 500 ETF (SPY)
Day One Biopharmaceuticals Business Overview & Revenue Model
Day One Biopharmaceuticals Earnings Call Summary
Day One Biopharmaceuticals Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 133.67M | 131.16M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 119.56M | 125.88M | -383.00K | -531.00K | -199.00K | -155.00K |
| EBITDA | -141.73M | -86.32M | -188.53M | -141.65M | -72.56M | -43.66M |
| Net Income | -151.76M | -95.50M | -188.92M | -142.18M | -70.64M | -40.51M |
Balance Sheet | ||||||
| Total Assets | 513.78M | 582.79M | 376.05M | 349.06M | 289.82M | 45.66M |
| Cash, Cash Equivalents and Short-Term Investments | 451.58M | 531.72M | 366.35M | 342.27M | 284.31M | 43.73M |
| Total Debt | 2.89M | 2.60M | 408.00K | 813.00K | 220.00K | 402.00K |
| Total Liabilities | 62.91M | 80.04M | 29.51M | 17.02M | 8.67M | 2.20M |
| Stockholders Equity | 450.87M | 502.75M | 346.54M | 332.04M | 281.15M | 37.76M |
Cash Flow | ||||||
| Free Cash Flow | -121.36M | -80.28M | -150.08M | -109.90M | -56.54M | -13.58M |
| Operating Cash Flow | -119.62M | -78.11M | -146.85M | -109.87M | -48.54M | -13.49M |
| Investing Cash Flow | -262.47M | -230.99M | 128.38M | -255.07M | -8.00M | -92.00K |
| Financing Cash Flow | 2.60M | 203.29M | 164.00M | 165.90M | 297.12M | 29.98M |
Day One Biopharmaceuticals Technical Analysis
Day One Biopharmaceuticals Risk Analysis
Day One Biopharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $1.02B | 35.57 | 14.03% | ― | 27.12% | ― | |
65 Neutral | $1.11B | -6.84 | -30.16% | ― | 31.11% | -46.75% | |
63 Neutral | $775.33M | -3.41 | -65.10% | ― | ― | -5.18% | |
54 Neutral | $1.23B | -17.26 | -22.38% | ― | 2147.20% | -269.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $943.56M | -4.64 | -41.06% | ― | -30.56% | 48.79% | |
47 Neutral | $567.07M | -3.67 | ― | ― | -58.17% | -116.24% |
Day One Biopharmaceuticals Corporate Events
On January 11, 2026, Day One Biopharmaceuticals reported preliminary unaudited 2025 OJEMDA net product revenue of $155.4 million, up 172% year over year, with fourth-quarter sales of about $52.8 million driven by rising patient demand and 1,394 prescriptions in the quarter. The company issued 2026 U.S. net product revenue guidance for OJEMDA of $225 million to $250 million, implying roughly 53% growth at the midpoint, and highlighted a cash, cash equivalents and short-term investment position of about $441.1 million as of December 31, 2025, prior to the Mersana acquisition, underscoring its capacity to fund ongoing commercialization and clinical programs. Management outlined 2026 priorities including expanding OJEMDA’s commercial footprint and solidifying its role as standard of care in second-line pediatric low-grade glioma, completing enrollment in the pivotal Phase 3 FIREFLY-2 trial in first-line pLGG in the first half of 2026, and delivering Phase 1 data for Emi-Le by mid-2026 and initial Phase 1a data for DAY301 in the second half of 2026, positioning the company for further growth and potentially broader oncology indications.
The most recent analyst rating on (DAWN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Day One Biopharmaceuticals stock, see the DAWN Stock Forecast page.
On January 6, 2026, Day One Biopharmaceuticals completed its acquisition of Mersana Therapeutics in an all-cash tender offer and follow-on merger, paying $25 per share plus a non-tradable contingent value right (CVR) per share that could deliver additional milestone payments of up to $30.25, for potential total consideration of $55.25 per share. The deal, funded with approximately $128.8 million of Day One’s cash on hand, results in Mersana becoming a wholly owned subsidiary and its stock being delisted from Nasdaq, while former Mersana shareholders receive the same mix of cash and CVRs whether they tendered in the offer or were converted in the merger. Each CVR entitles holders to a series of potential cash milestone payments tied to U.S. regulatory designations, clinical trial progress, FDA approval, commercial launches in major global markets, and specified annual net sales thresholds for Emi-Le, with deadlines running from 2026 through 2037, though these milestones are not guaranteed and the CVRs are generally non-transferable. Strategically, the transaction expands Day One’s oncology portfolio with a second clinical-stage antibody-drug conjugate and deepens its push into adult and rare cancers, notably ACC, as the company looks to build on momentum from OJEMDA and position itself as a more diversified player in targeted oncology while assuming the integration and development risks associated with the acquisition and milestone structure.
The most recent analyst rating on (DAWN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Day One Biopharmaceuticals stock, see the DAWN Stock Forecast page.
On November 24, 2025, Day One Biopharmaceuticals announced three-year results from its OJEMDA™ (tovorafenib) pivotal Phase 2 FIREFLY-1 trial, presented at the Society for Neuro-Oncology Annual Meeting. The updated data showed that 58% of patients completed 26 or more cycles of treatment, with a 53% overall response rate and a median duration of response of 19.4 months. The trial demonstrated that patients could maintain disease control during extended periods off therapy, with minimal tumor rebound and the option to reinitiate treatment if needed. These findings highlight tovorafenib’s potential as a second-line standard of care for pediatric low-grade glioma, offering patients meaningful time away from treatment.
The most recent analyst rating on (DAWN) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Day One Biopharmaceuticals stock, see the DAWN Stock Forecast page.
On November 12, 2025, Day One Biopharmaceuticals announced a merger agreement to acquire Mersana Therapeutics, aiming to expand its oncology portfolio with Mersana’s novel ADC, emiltatug ledadotin (Emi-Le), which shows promise in treating adenoid cystic carcinoma type-1. The acquisition, valued at up to $285 million, is expected to close by January 2026, subject to regulatory approvals. This strategic move is anticipated to enhance Day One’s market position by leveraging its existing capabilities to develop and potentially commercialize Emi-Le, addressing unmet needs in cancer treatment.
The most recent analyst rating on (DAWN) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Day One Biopharmaceuticals stock, see the DAWN Stock Forecast page.
Day One Biopharmaceuticals reported its third quarter 2025 financial results, highlighting a strong commercial performance of OJEMDA, with net product revenue reaching $38.5 million, a 15% increase from the previous quarter. The company raised its full-year 2025 net product revenue guidance to $145 to $150 million, reflecting strong demand. The company also announced progress in its clinical trials, including the Phase 3 FIREFLY-2 trial and the Phase 1a trial of DAY301, and noted the addition of tovorafenib to the NCCN treatment guidelines. Despite a net loss of $19.7 million for the quarter, Day One ended the period with $451.6 million in cash and investments, positioning it well for future growth.
The most recent analyst rating on (DAWN) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Day One Biopharmaceuticals stock, see the DAWN Stock Forecast page.